Kepler Capital Markets set a €106.00 ($123.26) price objective on Merck KGaA (FRA:MRK) in a report released on Wednesday. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other equities research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. reaffirmed a neutral rating and set a price objective on shares of Merck KGaA in a research report on Tuesday, September 11th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the stock a buy rating in a research report on Thursday, August 9th. Warburg Research set a €100.00 ($116.28) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, August 28th. Goldman Sachs Group set a €92.00 ($106.98) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, September 4th. Finally, Barclays set a €70.00 ($81.40) price objective on shares of Merck KGaA and gave the stock a sell rating in a research report on Friday, August 24th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of Hold and an average price target of €98.81 ($114.89).
MRK opened at €86.26 ($100.30) on Wednesday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: Fiduciary
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.